ANA Therapeutics ( SOSV Accelerator)

Funding Details
Awarder
SOSV
Date Award
May 13, 2024
Vertical
Therapeutics
Funding URL
View Funding Page
Company Info
Founding Year
Not provided in the memo
Organizations Involved
Not provided in the memo
Founders
Not provided in the memo
Company Description
ANA Therapeutics developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19. ANA Therapeutics was acquired by NeuroBo Pharmaceuticals in 2020.
Market
COVID-19 Treatment
Location
United States
Links
Back to Home Back to Therapeutics Deals View Funding Announcement